A Phase 1 Study Evaluating ASTX727 (decitabine and cedazuridine) and Venetoclax Combination Therapy in Newly Diagnosed AML Patients Unfit for Intensive Induction Chemotherapy

被引：0

作者：

Nannis, Gabriel N. ^{[1
]}

Griffiths, Elizabeth A. ^{[2
]}

Savona, Michael R. ^{[3
]}

Odenike, Olatoyosi ^{[4
]}

Roboz, Gail J. ^{[5
]}

O'Connell, Casey L. ^{[6
]}

Dillingham, Jacqueline ^{[7
]}

Wason, Prieya ^{[7
]}

Zhu, Lixia ^{[7
]}

Chan, Danna ^{[7
]}

Keer, Harold N. ^{[7
]}

Oganesian, Aram ^{[7
]}

Dao, Kim-Hien ^{[7
]}

DiNardo, Courtney D. ^{[8
]}

机构：

[1] Stanford Univ, Div Hematol, Dept Med, Sch Med, Stanford, CA USA

[2] Roswell Pk Comprehens Canc Ctr, New York, NY USA

[3] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Sch Med, Nashville, TN USA

[4] Univ Chicago, Chicago, IL USA

[5] New York Presbyterian Hosp, Weill Cornell Med, New York, NY USA

[6] Univ Southern Calif, USC Keck Sch Med, Los Angeles, CA USA

[7] Astex Pharmaceut Inc, Pleasanton, CA USA

[8] Univ Texas MD, Anderson Canc Ctr, Houston, TX USA

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-146264

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1245

引用

页数：5

共 50 条

[21] Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy
Bhatnagar, Bhavana
Duong, Vu H.
Gourdin, Theodore S.
Tidwell, Michael L.
Chen, Ching
Ning, Yi
Emadi, Ashkan
Sausville, Edward A.
Baer, Maria R.
LEUKEMIA & LYMPHOMA, 2014, 55 (07) : 1533 - 1537
[22] A Randomized Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy
Short, Nicholas J.
Sedarati, Farhad
Zhao, Dan
Tsukurov, Olga
Friedlander, Sharon
Faller, Douglas V.
BLOOD, 2020, 136
[23] Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study
Stein, Eytan M.
DiNardo, Courtney D.
Fathi, Amir T.
Mims, Alice S.
Pratz, Keith W.
Savona, Michael R.
Stein, Anthony S.
Stone, Richard M.
Winer, Eric S.
Seet, Christopher S.
Doehner, Hartmut
Pollyea, Daniel A.
McCloskey, James K.
Odenike, Olatoyosi
Loewenberg, Bob
Ossenkoppele, Gert J.
Patel, Prapti A.
Roshal, Mikhail
Frattini, Mark G.
Lersch, Frederik
Franovic, Aleksandra
Nabhan, Salah
Fan, Bin
Choe, Sung
Wang, Hongfang
Wu, Bin
Hua, Lei
Almon, Caroline
Cooper, Michael
Kantarjian, Hagop M.
Tallman, Martin S.
BLOOD, 2021, 137 (13) : 1792 - 1803
[24] A phase 1/2 study of gilteritinib in combination with chemotherapy in newly diagnosed patients with AML in Asia
Sawa, Masashi
Miyamoto, Toshihiro
Kim, Hee-Je
Hiramatsu, Yasushi
Cheong, June-Won
Ikezoe, Takayuki
Naoe, Tomoki
Akashi, Koichi
Morita, Satoshi
Kosako, Masanori
Ikegaya, Moyu
Terada, Wataru
Kadokura, Takeshi
Hill, Jason
Miyawaki, Shuichi
Gill, Stanley C.
Heinloth, Alexandra
Hasabou, Nahla
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2025, 121 (01) : 56 - 67
[25] A Phase Ib/II Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML
Aboudalle, Iman
Konopleva, Marina Y.
Kadia, Tapan M.
Naqvi, Kiran
Vaughan, Kenneth
Kurt, Mehmet
Cavazos, Antonio
Pierce, Sherry A.
Takahashi, Koichi
Masarova, Lucia
Yilmaz, Musa E.
Jabbour, Elias
Garcia-Manero, Guillermo
Kornblau, Steven M.
Ravandi, Farhad
Cortes, Jorge
Kantarjian, Hagop M.
DiNardo, Courtney D.
BLOOD, 2019, 134
[26] Initial Results from SELECT-AML-1, a Phase 2 Study of Tamibarotene in Combination with Venetoclax and Azacitidine in RARA-Positive Newly Diagnosed AML Patients Ineligible for Standard Induction Chemotherapy
Kambhampati, Suman
McMahon, Christine M.
Eghtedar, Alireza
Pollyea, Daniel A.
de Botton, Stephane
Pigneux, Arnaud
Cherry, Mohamad
Ball, Brian J.
Borthakur, Gautam
Cluzeau, Thomas
Schiller, Gary J.
Hu, Beibei
Volkert, Angela
Gausman, Joanie Aasen
Hodgson, Graeme
Roth, David A.
Warlick, Erica D.
Kelly, Michael J.
Stein, Eytan
BLOOD, 2022, 140 : 3333 - 3335
[27] Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML
Lachowiez, Curtis
Konopleva, Marina
Kadia, Tapan M.
Daver, Naval
Loghavi, Sanam
Wang, Sa A.
Adeoti, Maria
Pierce, Sherry A.
Takahashi, Koichi
Short, Nicholas J.
Sasaki, Koji
Borthakur, Gautam
Issa, Ghayas C.
Wierda, William G.
Pemmaraju, Naveen
Bravo, Guillermo Montalban
Ferrajoli, Alessandra
Jain, Nitin
Masarova, Lucia
Yilmaz, Musa
Jabbour, Elias
Garcia-Manero, Guillermo
Kornblau, Steven M.
Ravandi, Farhad
Kantarjian, Hagop M.
Dinardo, Courtney D.
BLOOD, 2020, 136
[28] The Efficacy and Safety of the Combination Therapy of Decitabine, Venetoclax, and Selinexor (DVS) for Newly Diagnosed Unfit AML and MDS, and Relapsed/ Refractory AML and High-Risk MDS- a Multicenter, Single Arm, Prospective Clinical Study
Xing, Lina
Guo, Zijing
Huang, Chen
Jing, Hongmei
Qiao, Shukai
BLOOD, 2024, 144 : 6057 - 6058
[29] Phase 1 Trial Testing the Novel Combination Therapy of Entrectinib and ASTX727 in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia Patients
Tognon, Cristina
Mishra, Shikha
Kaempf, Andy
Park, Byung
Joshi, Sunil K.
Huang, Ariane
Kurtz, Stephen E.
Sax, Luca
Eide, Christopher A.
Johnson, Kara
Mahoney, Rachel
Lue, Michael James
Tong, Nicole
Guiducci, Lisa
Willians, Tara Lundberg
Solanki, Emma Indira
Cook, Rachel J.
Leonard, Jessica T.
Lachowiez, Curtis A.
Meyers, Gabrielle
Saultz, Jennifer N.
Traer, Elie
Tyner, Jeffrey W.
Borate, Uma
Swords, Ronan T.
BLOOD, 2024, 144 : 1498 - 1499
[30] Phase 1/2 Study of Sapacitabine and Decitabine Administered Sequentially in Elderly Patients with Newly Diagnosed AML
Ravandi, Farhad
Faderl, Stefan
Cortes, Jorge E.
Garcia-Manero, Guillermo
Jabbour, Elias
Boone, Patricia Ann
Kadia, Tapan
Borthakur, Gautam
Wierda, William G.
Wetzler, Meir
Venugopal, Parameswaran
Chiao, Judy
Kantarjian, Hagop M.
BLOOD, 2011, 118 (21) : 1550 - 1551

← 1 2 3 4 5 →